Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate

May. 14, 2024

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; "Sumitomo Pharma") and National Institutes of Biomedical Innovation, Health and Nutrition (Ibaraki, Osaka, Japan; President: Yusuke Nakamura; "NIBIOHN") have been working on the development of a universal influenza vaccine with prophylactic efficacy against a wide range of influenza viruses under the Cyclic Innovation for Clinical Empowerment program conducted by Japan Agency for Medical Research and Development .

Sumitomo Pharma and NIBIOHN announced today that they have commenced a Phase 1 clinical study on "fH1/DSP-0546LP", a universal influenza vaccine candidate formulation, in Europe.

Please click here for the detail.